Search Results

Novo CEO Maziar Mike Doustdar disclosed an additional 4,000 staff departures, which a spokesperson told BioSpace are linked to attrition and other measures.

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.

• Vial’s IL-13 x TSLP is designed to deliver breadth, depth, and durability of Type 2 disease control in a single half-life-extended antibody • Phase 1a data in healthy volunteers (15–800 mg IV) support progression into patients, with pharmacokinetics that could support twice-yearly (Q6M) dosing • Phase 1b study will evaluate safety, tolerability, pharmacokinetics, and FeNO-based proof-of-mechanism in patients with mild-to-moderate asthma • Interim Phase 1b data readout expected in H1 2027

Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.